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a  b  s  t  r  a  c  t
Background:  The  protection  elicited  by polysaccharide  pneumococcal  vaccines  against  community-
acquired  pneumonia  in  older  adults  remains  debatable.  Alternative  vaccine  targets  include
well-conserved  pneumococcal  protein  antigens,  such  as  pneumococcal  histidine  triad  protein  D  (PhtD).
Objective:  To  evaluate  humoral  and  cellular  immune  responses  and safety/reactogenicity  following
immunisation  with  PhtD  vaccine  with  or without  adjuvant  (alum  or AS02V) in  older  (≥65  years)  and
young  (18–45  years)  healthy  adults.
Methods:  Two  phase  I/II, single-blind,  parallel-group  studies  were  conducted  in  150 older  and  147 young
adults.  Participants  were  randomised  to receive  2 doses  (months  0 and  2)  of PhtD  30 g,  PhtD  10  g
plus  alum,  PhtD 30 g plus  alum,  PhtD  10 g  plus  AS02V or PhtD  30 g plus  AS02V, or the  23-valent
polysaccharide  pneumococcal  vaccine  (23PPV)  at month  0 with placebo  (saline  solution)  at  month  2.
Safety/reactogenicity  was  assessed.  PhtD-speciﬁc  antibody,  T cell  and  memory  B cell  responses  were
evaluated.
Results:  Solicited  adverse  events  were  more  common  in young  participants  and  with  adjuvanted  vaccines.
No  vaccine-related  serious  adverse  events  were  reported.  Although  anti-PhtD  geometric  mean  antibody
concentrations  (GMCs)  were  consistently  lower  in the older  adult  cohort  than  in young  adults,  GMCs
in the  older  cohort  following  PhtD 30  g plus  AS02V were  comparable  to those  induced  by plain  PhtD
or  PhtD  30  g  plus  alum  in the  young  cohort.  Compared  with  alum  adjuvant,  AS02V adjuvant  system
was associated  with  an  increased  frequency  of PhtD-speciﬁc  CD4  cells  in  both  cohorts  and  a signiﬁcantly
higher  speciﬁc  memory  B cell  response  in the  older  cohort,  similar  to  responses  obtained  in the  young
cohort.
Conclusion:  The  improved  imm
in  comparison  to alum  sugge
be partially  restored  to  the  
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. Introduction
It is widely accepted that ‘immunosenescence’, the deteriora-
ion of immune function with advancing age, also contributes to
he increased incidence of morbidity and mortality from infectious
iseases among older adults [1] and reduced responses to vacci-
ation [2–4]. The 23-valent polysaccharide pneumococcal vaccine
23PPV) is recommended for use in older adults in most countries
ut, while there is evidence for a signiﬁcant reduction in the risk
f pneumococcal bacteraemia, protection against non-bacteraemic
neumonia in this population has been a matter of debate [5–9].
eing T cell independent, polysaccharide antigens also fail to induce
dequate immunological memory and improved responses upon
evaccination [10]. Polysaccharide pneumococcal conjugate vac-
ines (PCVs) elicit a better priming response in adults [11] but
heir impact on clinical respiratory outcomes in this population
emains to be established. Also, the introduction of PCVs into paedi-
tric vaccination programmes led to a decrease in vaccine serotype
neumococcal disease in adults, which may  limit the beneﬁt of
CVs with same serotype composition in older age groups [9,12].
Common pneumococcal proteins are interesting candidate anti-
ens for new pneumococcal vaccines, since they offer the potential
or serotype-independent coverage through either antibody or cel-
ular responses [13–18]. The pneumococcal histidine triad protein
 (PhtD) is one such conserved pneumococcal protein antigen that
as been shown to elicit functional antibodies [19–21] and provide
rotection against pneumonia in animal models [20,22]. The need
o improve immune responses in older adults has also led to the
earch for vaccine adjuvants that enhance the magnitude and qual-
ty of antigen-speciﬁc immune response [23]. AS02V is an adjuvant
ystem that consists of an oil-in-water emulsion combined with
wo potent immunostimulants, 3-O-desacyl-4′-monophosphoryl
ipid A (MPL) and the saponin QS21 (Quillaja saponaria Molina, frac-
ion 21; Antigenics Inc., a wholly owned subsidiary of Agenus Inc.,
exington, MA,  USA) [24].
Two studies were conducted to examine the immunogenicity
nd reactogenicity of two  doses of PhtD vaccine administered with
r without AS02V or alum adjuvant in healthy adults. The stud-
es were of identical design, apart from the age of participants:
ne study included adults aged 65 years or older, while the other
ncluded younger adults.
. Materials and methods
.1. Study design and participants
In the phase I/II, single-blind, parallel-group studies, older
≥65 years) and young (18–45 years) adults in generally good
ealth were eligible for inclusion. Major exclusion criteria
ncluded previous vaccination against Streptococcus pneumoniae or
ith a MPL/QS21-containing vaccine, administration of immune-
odifying drugs within the last 6 months, and bacterial pneumonia
ithin 3 years of the ﬁrst dose. A full list of inclusion/exclusion
riteria is provided in Appendices A and B.
Using a centralised randomisation system on the internet, par-
icipants were randomised (1:1:1:1:1:1) by the investigator at each
ite to receive vaccination at 0 and 2 months with PhtD 30 g, PhtD
0 g plus alum (aluminium phosphate, AlPO4), PhtD 30 g plus
lum, PhtD 10 g plus AS02V or PhtD 30 g plus AS02V, or 23PPV
PneumovaxTM; Sanoﬁ Pasteur MSD, Lyon, France) at month 0 fol-
owed by placebo (saline solution) at month 2 (control group). The
tudies were single-blind, meaning that participants were unaware
f the vaccination assignment.
Co-primary objectives of the studies were to evaluate the safety,
eactogenicity and immunogenicity of plain or adjuvanted PhtD,e 33 (2015) 577–584
with evaluation of the persistence and quality of the antibody
response, and cellular immune response as secondary objectives.
The young cohort study was  conducted at the Catholic University of
Louvain, Brussels, Belgium, between October 2003 and November
2004 and the older cohort study was conducted at the Centre for
Vaccinology, Ghent University Hospital, Belgium, between January
2004 and March 2005 followed by additional 2-year follow-up; 1-
year results are presented for both cohorts. All participants gave
written informed consent to the studies, which were approved
by local ethics committees and conducted in accordance with the
Declaration of Helsinki.
2.2. Vaccines
The PhtD vaccine was  supplied as freeze-dried pellets in mon-
odose vials to be reconstituted with phosphate buffered saline or
with adjuvant formulation AS02V liquid in pre-ﬁlled syringes, or
was supplied adsorbed on alum as a liquid in monodose vials.
23PPV was supplied in pre-ﬁlled syringes and placebo saline in
monodose vials. Inﬂuenza vaccine (FluarixTM; GlaxoSmithKline,
Rixensart, Belgium) was offered free of charge to the older cohort
during the study. All study vaccines were administered by intra-
muscular injection (0.5 ml)  into the deltoid region of the upper
right arm. Participants were observed closely for at least 30 min
after vaccination.
2.3. Reactogenicity and safety assessment
Solicited local (injection site pain, redness and swelling)
and general (fatigue, fever, gastrointestinal symptoms, headache,
malaise, myalgia and sweating) adverse events (AEs) were recorded
by the participants on diary cards during the 7-day follow-up after
each vaccination. Unsolicited AEs were recorded within 30 days
after each vaccination. Serious AEs were reported throughout the
study. Duration, causality and outcome of AEs were recorded. All
solicited local reactions were considered causally related to vacci-
nation; the relationship of other AEs was  classiﬁed as possible or
not causally related. AE intensity was scored on a scale from 1 to 3.
Grade 3 AEs were deﬁned as preventing normal daily activity, apart
from grade 3 solicited fever, which was  deﬁned as oral/axillary tem-
perature >39.0 ◦C, and grade 3 solicited swelling or redness, deﬁned
as diameter >50 mm.  Grade 2 pain was  deﬁned as painful when the
limb was moved.
2.4. Immunogenicity assays
In both cohorts, blood samples were taken within 14 days
before the ﬁrst vaccination and at post-vaccination intervals up
to 10 months after the second vaccine dose. All blood samples
were processed and stored appropriately until analysed using in-
house methods at the laboratories of GlaxoSmithKline, Rixensart,
Belgium.
Anti-PhtD antibody concentrations were measured at months
0 (before the ﬁrst vaccine dose), 1, 2 (before the second dose), 3
and 12 using an enzyme-linked immunosorbent assay (ELISA; assay
cut-off 0.04 g/ml), as described previously [22]. A passive transfer
mouse model assay was  used to evaluate the protection provided
by anti-PhtD antibodies in pooled sera collected at months 0 and 3
from participants who received PhtD 30 g, PhtD 30 g plus alum
or PhtD 30 g plus AS02V. Sera from each vaccine group were
administered intraperitoneally into OF1 mice 1 h before intranasal
challenge with a lethal dose (105 cfu) of S. pneumoniae serotype 3.
Mortality induced by infection was  monitored for 10 days. A rabbit
anti-PhtD antiserum, generated in-house using recombinant PhtD
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In the groups that received PhtD 30 g plus alum or PhtD 30 g
lus AS02V, the frequencies of PhtD-speciﬁc IgG-producing mem-
ry B cells induced after vaccination were assessed by B cell Elispot
25] after in vitro differentiation for 5 days. The frequencies of
htD-speciﬁc CD4 or CD8 T cells induced after vaccination were
etermined by intracellular cytokine ﬂow cytometry and were
dentiﬁed as CD4+/CD8+ T cells producing one or more markers
mong interferon (IFN)-,  interleukin (IL)-2, IL-4 and/or tumour
ecrosis factor (TNF)- for the ﬁrst intracellular staining and among
D40L, granulocyte-macrophage colony-stimulating factor (GM-
SF), IL-2 and/or TNF- for the second intracellular staining upon
hort term in vitro stimulation with PhtD overnight for 18 h. Choice
f markers was based on practicability and knowledge of their roles
n the vaccine-induced cell-mediated immune response. IFN- is
 critical cytokine for innate and adaptive immunity and charac-
erises Th1 T cells [26], while IL-2 is a cytokine associated with
emory T cells and T cell proliferation and differentiation [27] and
L-4 characterises Th2 T cells [28]. TNF- is a pro-inﬂammatory
ytokine that is also a neutrophil chemoattractant [29] and CD40L,
hich is a co-stimulatory ligand required for T cell help that
lso induces the differentiation of B cells [30,31] and, as it is
xpressed on activated CD4+ cells, allows the sensitivity of the
ntracellular staining assay to be improved [32,33]. GM-CSF stimu-
ates the growth and differentiation of haematopoietic precursor
ells from various lineages, including granulocytes, macrophages,
osinophils, and erythrocytes, and has the capacity to increase
ntigen-induced immune responses and alter the Th1/Th2 cytokine
alance [34].
Intracellular cytokine ﬂow cytometry methods were as
escribed by Maecker et al. [35] and Moris et al. [36], except that
n vitro stimulation was performed using a pool of 20-mer peptides
1.25 g/ml) that overlapped by 10 amino acids and covered the
equence of the relevant antigens. Anti-CD4-PerCP and anti-CD8-
PC-Cy7 were used for extracellular staining, and for intracellular
taining, either anti-CD40L-FITC, anti-IL-2-APC, anti-GM-CSF-PE
nd anti-TNF-PE-Cy7 or BD SimultestTM anti-IFN--FITC/anti-IL-
-PE, anti-IL-2-APC and anti-TNF--PE were used. Representative
ating strategy for ﬂow cytometry is shown in Appendices A and B.
he frequencies of CD4+ T cells expressing each marker after in vitro
timulation are presented.
.5. Statistical analyses
In each study, 92 subjects (23 per group) were required to assess
djuvant type (alum or AS02V) and antigen concentration (PhtD
0 g or 30 g). The assumed standard deviation was  0.5 and con-
idered effect size was 0.4 to achieve >90% power with an F test of
ach factor at 5% signiﬁcance level. Two groups of identical sizes
ere added as controls. Therefore, the target sample size for the
wo studies combined was 300 enrolled subjects (25 per group) in
rder to achieve 276 evaluable subjects (23 per group).
All evaluable participants (i.e. those meeting all eligibility crite-
ia, complying with the procedures deﬁned in the protocol, with
o elimination criteria during the study, for whom immunogenic-
ty data were available) were included in the according-to-protocol
ATP) cohort for analysis of immunogenicity. Anti-PhtD geometric
ean antibody concentrations (GMCs) were calculated with 95%
onﬁdence intervals (CIs). The anti-PhtD antibody response one
onth after each vaccine administration was compared between
roups using a two-way ANOVA model on log10 transformed data.
he model included the antigen dose (PhtD 10 g or 30 g), type
f adjuvant (alum or AS02V) and antigen dose by type of adjuvant
nteraction as factors.
The frequencies of CD4/CD8 T cells that produced cytokines, and
he frequencies of PhtD-speciﬁc plasma cells generated by in vitro
ultured memory B cells, were compared at month 3 between thee 33 (2015) 577–584 579
PhtD 30 g plus alum and PhtD 30 g plus AS02V groups using the
Wilcoxon rank-sum test. In the antibody passive transfer assay,
time to death in mice was  estimated non-parametrically by the
Kaplan–Meier method and was  calculated from day 0 (day of trans-
fer) to the day of death or censoring at day 10. The passive transfer
protection data presented are qualitative only as the model used
does not have the capacity to show differences between vaccines.
The safety analysis was  conducted on the total vaccinated cohort.
3. Results
3.1. Study population
A total of 147 and 150 subjects were enrolled and vaccinated
in the young adult and older adult studies, respectively, and 144
and 147 participants, respectively, were included in the ATP cohort
for immunogenicity. Reasons for exclusion from the ATP cohort for
immunogenicity and withdrawals are provided in Appendices A
and B. The demographic characteristics of all groups were compa-
rable with respect to median age and ethnic origin, while the female
to male ratio varied (Table 1).
3.2. Reactogenicity and safety
Overall, solicited local and general AEs were more common in
the young cohort than in the older cohort (Fig. 1). Reactogenicity
tended to be higher in the AS02V groups than in the other groups
but, in all groups that received adjuvanted vaccine, there was  no
consistent evidence to suggest greater reactogenicity with PhtD
30 g versus the 10 g dose.
Pain was  the most common solicited local AE in both young
and older participants and its incidence was highest with PhtD
plus AS02V in both groups (Fig. 1). In the young cohort, after the
ﬁrst dose, 13, 2, 5, 11, 15 and 18 subjects reported grade 2 (max-
imum severity over the solicited period) injection site pain in the
23PPV, PhtD 30 g, PhtD 10 g plus alum, PhtD 30 g plus alum,
PhtD 10 g plus AS02V and PhtD 30 g plus AS02V groups, respec-
tively. All grade 2 pain lasted a maximum of two consecutive days
except one report in the PhtD 30 g plus AS02V group, which lasted
three days. Grade 3 pain was  reported by four subjects in the 23PPV
group, four in the PhtD 10 g plus AS02V group and one subject in
the PhtD 30 g plus AS02V group. All grade 3 pain lasted a maxi-
mum of two  consecutive days. After the second dose, 0, 1, 3, 9, 11
and 19 subjects reported grade 2 injection site pain in the 23PPV
(placebo as second injection), PhtD 30 g, PhtD 10 g plus alum,
PhtD 30 g plus alum, PhtD 10 g plus AS02V and PhtD 30 g plus
AS02V groups, respectively. All grade 2 pain lasted a maximum
of two  consecutive days, apart from ﬁve consecutive days for one
subject in the PhtD 10 g plus alum group, and three and four con-
secutive days for two subjects in the PhtD 30 g plus AS02V group.
Grade 3 pain was reported by seven subjects in the PhtD 10 g plus
AS02V group and by two in the PhtD 30 g plus AS02V group. All
grade 3 pain lasted a maximum of two consecutive days.
In the older cohort, up to eight subjects in each study group
reported grade 2 injection site pain after the ﬁrst dose and up to
seven reported grade 2 pain after the second dose, with the highest
incidences in the AS02V groups. All grade 2 pain lasted a maximum
of two consecutive days, except for grade 2 pain in two subjects in
the PhtD 10 g plus alum group (three consecutive days post-dose
1 or seven days post-dose 2) and one subject in the PhtD 30 g plus
AS02V group (three days post-dose 2). No grade 3 pain was reported
in the older cohort.
In the young cohort, there were few reports of grade 3 redness
or swelling (≤3 reports of each grade 3 event in each group). In
older participants, there was one report each of grade 3 redness
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Table 1
Demographics of participants (ATP cohorts for immunogenicity).
Group 23PPV PhtD 30 g PhtD 10 g + alum PhtD 30 g + alum PhtD 10 g + AS02V PhtD 30 g + AS02V
Young adult cohort (18–45 years), n 24 24 23 25 23 25
Median age, years 27.5 25.0 27.0 27.0 26.0 25.0
Age  range, years 18–43 19–44 19–45 18–45 18–44 19–39
Gender (%), female/male 62.5/37.5 29.2/70.8 52.2/47.8 32.0/68.0 52.2/47.8 52.0/48.0
Ethnicity (%)
Caucasian 100 91.7 87.0 96.0 91.3 96.0
Older  adult cohort (≥65 years), n 25 25 24 25 25 23
Median age, years 73.0 72.0 72.5 73.0 69.0 70.0
Age  range, years 65–83 66–80 66–84 65–82 65–78 65–80


















gCaucasian 100 100 100 
ollowing 23PPV and grade 3 swelling following PhtD 30 g plus
S02V.
Fatigue and headache were the most commonly reported
olicited general symptoms in both cohorts. There were no reports
f grade 3 solicited general symptoms in the older cohort, apart
rom one report of grade 3 malaise in the PhtD 10 g plus AS02V
roup. There was one report of fever (38.4 ◦C) in the PhtD 30 g
lus AS02V group of the older cohort that lasted one day (on day 5
ost-dose 2). In the young cohort, one to ﬁve subjects in each study
roup (maximum in PhtD 30 g plus AS02V group) reported fever
fter vaccination that lasted for a maximum of two  consecutive
ays and occurred mainly on day 0 and/or day 1 after vaccination.
ll but two were <38.5 ◦C, with no reports of grade 3 fever (>39 ◦C).
rade 3 fatigue followed 2.0%, 4.3% and 8.2% of PhtD 10 g plus
lum, PhtD 10 g plus AS02V and PhtD 30 g plus AS02V doses,
ig. 1. Overall per dose incidence (with 95% conﬁdence intervals) of solicited local ((A) a
accine dose in young ((A) and (B)) and older ((C) and (D)) adult participants (total vacc
roups  were administered PhtD (30 g or 10 g) with or without adjuvant (AS02v or alum100 100 100
respectively, while reports of other grade 3 solicited general AEs
were infrequent (≤3 reports of each grade 3 event in each group).
The overall incidence of unsolicited AEs was comparable
between groups for both cohorts (data in Appendices A and B).
There were no reports of grade 3 unsolicited AEs causally related to
vaccination in the older cohort and one report each of grade 3 ‘feel-
ing cold’ and tremor possibly related to vaccination in the young
cohort (both in PhtD 30 g plus AS02V group). No vaccine-related
serious AEs were reported during the study.
3.3. Humoral immunityAt all time points, all participants in both cohorts were seropos-
itive for antibodies against PhtD (cut-off 0.04 g/ml). Anti-PhtD
GMCs were consistently lower in the older cohort than in the young
nd (C)) and general ((B) and (D)) symptoms within the 7 day follow-up after each
inated cohorts). 23PPV, 23-valent polysaccharide pneumococcal vaccine. All other
). GI, gastrointestinal.











































lig. 2. Anti-PhtD antibody geometric mean concentrations (GMCs with 95% conﬁd
rst  (M1) and second vaccine doses (M3) and ten months after second dose (M12) 
ohort before vaccination and after each vaccine dose; after the ﬁrst
ose, GMC  responses in the young cohort were similar to those after
he second dose in the older cohort (Fig. 2). In the older cohort, the
nti-PhtD GMC  after the second dose of PhtD 30 g plus AS02V
143.7 g/ml [95% CI 103.5; 199.5]) was comparable to that in the
oung cohort after the second dose of plain PhtD 30 g or PhtD
0 g plus alum (124.2 g/ml [95% CI 89.3; 172.8]) and 144.8 g/ml
95% CI 114.5; 183.2], respectively) (Fig. 2).
In both cohorts, no statistically signiﬁcant interactions between
ntigen dose and adjuvant were detected in the two-way ANOVA
odels, indicating that the dose effect (10 g versus 30 g PhtD)
id not depend on the adjuvant (AS02V or alum) and vice versa. The
NOVA model showed a statistically signiﬁcant dose effect, with
 higher anti-PhtD antibody response with PhtD 30 g than with
htD 10 g after each vaccine dose in both the older (p = 0.0051
fter dose 1, p = 0.0015 after dose 2) and young cohorts (p = 0.0034
fter dose 1, p = 0.0007 after dose 2). There was also a statistically
igniﬁcant adjuvant effect after dose 2, indicating a higher antibody
esponse with AS02V versus alum in both cohorts (p = 0.0002 in the
lder cohort, p < 0.0001 in the young cohort). No statistical differ-
nce between the PhtD 30 g and the PhtD 30 g plus alum groups
ould be detected in terms of anti-PhtD antibody response in either
ohort (data not shown), although the studies were not designed
r powered to make this comparison between groups.
In both cohorts, anti-PhtD GMCs were higher 10 months after
he second vaccine dose than before vaccination for all PhtD
accine groups; GMCs remained 2.6- to 4.3-fold higher than pre-
accination in the young cohort and 2.0- to 4.6-fold higher in the
lder cohort, with the highest fold increases in the AS02V groups
Fig. 2).
.4. Antibody passive transfer in mice
The biological functionality of the anti-PhtD antibodies from
articipants who received PhtD 30 g with or without adjuvant was
valuated by passive transfer of serum into naïve recipient mice
nfected with serotype 3 pneumococci. Fig. 3 details the per group
ouse survival following passive transfer of anti-PhtD antibod-
es from pre-vaccination and post-vaccination sera from vaccinees.
he improved survival rates observed in vaccine group PhtD 30 g
lus alum in the young adults, and in PhtD 30 g plus alum or PhtD
0 g plus AS02V in the older cohort, showed that the antibodies
enerated by the vaccines were functional. For the 3 other groups
plain PhtD 30 g in both cohorts or PhtD 30 g plus AS02V in young
dults), the absence of difference may  be explained by the higher
evels of functionality observed in the prevaccination samples.ntervals) in the young (A) and older (B) cohorts before (PRE), one month after the
ohorts for immunogenicity).
3.5. Cell mediated immunity
In both cohorts, memory B cells were boosted by PhtD vaccina-
tion with either adjuvant at one month after the second dose (Fig. 4).
In older participants, the increase in memory B cells was statisti-
cally signiﬁcantly greater with AS02V than with alum (p = 0.0045),
while there was no statistically signiﬁcant difference between adju-
vant groups in the young cohort (Fig. 4).
The frequencies of PhtD-speciﬁc CD4 T cells, identiﬁed in vitro as
expressing two or more cytokines for each of the two  intracellular
stainings (IFN-, IL-2, IL-4, TNF-; CD40L, GM-CSF, IL-2, TNF-),
were signiﬁcantly increased by vaccination with PhtD plus AS02V
compared with PhtD plus alum in both cohorts (Table 2). CD40L, IL-
2 and TNF- were the more prevalent expressed markers detected
upon in vitro stimulation. No CD8 T cell responses were detected
(data not shown).
4. Discussion
Vaccination against pneumococcal protein antigens, such as
PhtD, has the potential to offer broad, serotype-independent cover-
age [15,16]. In the present studies of vaccination with PhtD with or
without adjuvantation, solicited local and general reactions were
more common in young than in older adults. Reports of grade 3
solicited AEs were infrequent in older adults, with no reports of
grade 3 pain or general solicited symptoms. Overall, the reactogen-
icity proﬁle of AS02V was acceptable and similar to that reported
previously with the AS02V adjuvant system in healthy adults vac-
cinated with hepatitis B or HIV antigens [24,37].
A humoral immune response, as measured by anti-PhtD IgG
antibody concentration, was demonstrated to the pneumococcal
protein PhtD in the older cohort, although this was consistently
lower than in the young cohort. The greatest increases were
observed in the groups administered adjuvanted PhtD. In par-
ticular, use of AS02V was  associated with signiﬁcantly enhanced
anti-PhtD IgG responses in comparison with use of alum adjuvant
or plain PhtD vaccination, which was consistent with studies of
other vaccines using MPL- and QS21-containing adjuvant systems
[38]. AS02V adjuvantation also induced speciﬁc memory B cell and
CD4 T cell responses in both cohorts and, interestingly, the AS02V
combination induced signiﬁcantly higher speciﬁc memory B cell
levels as compared to the alum combination in the older cohort,
similar to those obtained in the young cohort, where no differ-
ence between adjuvants was observed. This suggests that AS02V
had a more pronounced effect on memory B cells in older adults
than alum, which is important in view of the signiﬁcant age-related
changes in the B cell repertoire that contribute to poor IgM memory
B cell responses to 23PPV in older persons [39,40]. The induction of
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Fig. 3. Mouse survival upon lethal S. pneumoniae intranasal challenge following passive transfer of anti-PhtD antibodies. Results shown from experiments of pooled sera
from  subjects. Blue dotted line: pre-vaccination serum: Red full line: post-vaccination serum. (For interpretation of the references to colour in this ﬁgure legend, the reader
is  referred to the web version of this article.)
Table 2
Frequency of CD4 T cells that produced IFN-, IL-2, IL-4, TNF-, CD40L and GM-CSF, measured in two intracellular cytokine staining assays, S1 and S2, in young and older
participants who  received PhtD 30 g plus alum or PhtD 30 g plus AS02V (total vaccinated cohorts). Production of two  or more of the markers (S1-All doubles and S2-All
doubles) or any of the markers (S1-IFN-, S1-IL-2, S1-IL-4, S1-TNF-, S2-CD40L, S2-GM-CSF, S2-IL-2, S2-TNF-) was evaluated before vaccination (PRE) and one month after
the  second vaccine dose (M3).
S1-All doubles S1-IFN- S1-IL-2 S1-IL-4 S1-TNF- S2-All doubles S2-CD40L S2-GM-CSF S2-IL-2 S2-TNF-
Young adult cohort, n = 50
PhtD + alum PRE 39.1 23.8 46.1 19.3 46.0 136.6 124.7 102.0 66.0 29.3
M3  649.8 245.4 630.8 50.5 538.3 1229.1 1080.8 429.8 1129.9 662.6
PhtD  + AS02V PRE 95.7 48.4 84.8 49.0 81.0 117.4 65.0 51.2 96.8 67.7
M3  1885.9 429.9 1846.1 119.6 1782.6 2692.6 2336.5 799.8 2439.2 1895.0
p  value* 0.0011 NS 0.0011 0.0225 0.0004 0.0004 0.0005 0.0023 0.0004 0.0001
Older adult cohort, n = 48
PhtD + alum PRE 59.8 41.8 33.0 39.6 33.5 78.8 39.3 48.0 57.4 57.7
M3  200.3 42.8 216.6 20.5 211.8 268.7 92.9 104.4 254.0 210.4
PhtD  + AS02V PRE 50.8 29.0 33.4 30.6 51.3 55.5 26.4 43.3 40.8 27.0
M3  799.0 81.6 858.0 19.1 833.0 1015.8 365.1 306.0 953.8 842.9
p  value* 0.003 NS 0.0001 NS 0.0001 0.0004 NS 0.0126 0.0002 0.0002
NS = not signiﬁcant.
* Wilcoxon rank-sum test, PhtD 30 g plus alum group versus PhtD 30 g plus AS02V group at M3.



































aig. 4. PhtD-speciﬁc memory B cells in the young (A) and older (B) cohorts before v
lispot  assay), expressed as frequency of PhtD-speciﬁc Ig-producing B cells per mill
D4 T cell responses in older adults is also signiﬁcantly higher upon
dministration with PhtD/AS02V as compared to PhtD/alum, which
s of note since preclinical evidence has suggested that enhancing
ged CD4 T cell function leads to improved antibody production
41] and that CD4 T cell interactions with pneumococci are crucial
n providing protection in the host [42]. The small sample sizes in
ach group of our study, however, restrict the ability to make ﬁrm
onclusions on immune responses induced by PhtD.
A pneumococcal lethal intranasal challenge mouse model was
sed to test the functionality of vaccine-induced antibodies. The
esults demonstrated the capacity of anti-PhtD elicited antibodies,
egardless of the vaccine, to induce protection against S. pneu-
oniae serotype 3, which is one of the serotypes associated with
n increased risk of fatal outcome in older people with invasive
neumococcal disease [43]. This was consistent with other demon-
trations of the functionality of human anti-PhtD antibodies in
ouse model studies [20,44]. In some groups, the absence of a dif-
erence between pre-vaccination and post-vaccination values was
ikely caused by the relatively high protective potential of baseline
era due to pre-existing antibodies to PhtD or other S. pneumoniae
ntigens resulting from previous pneumococcal exposure, hence
recluding the clear demonstration of an increased functionality
ost-vaccination.
These studies showed that vaccination with the pneumococcal
rotein PhtD elicits both CD4 T cell and memory B cell responses
n adults and that the reduced immune response in older per-
ons compared to young adults can be partially restored with
S02V adjuvant system. The anti-PhtD antibodies elicited post-
accination were shown to be functional. No safety concerns were
aised and AS02V-adjuvanted PhtD had an acceptable reactogeni-
ity proﬁle. An AS02V-adjuvanted PhtD vaccine may  therefore be
eneﬁcial in efforts to reduce the burden of pneumonia in the adult
opulation, including older persons.isclosure statement
Pneumovax is a trademark of Sanoﬁ Pasteur MSD  and Fluarix is
 trademark of the GlaxoSmithKline group of companies.ation (PRE) and one month after the second vaccine dose (M3) (measured by B cell
-producing memory B cells (ATP cohorts for immunogenicity).
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